<DOC>
	<DOCNO>NCT01027416</DOCNO>
	<brief_summary>This study help understand interaction hormonal therapy Tamoxifen , estrogen receptor certain gene cancer cell . This information may eventually help select appropriate therapy future patient similar cancer .</brief_summary>
	<brief_title>Analyzing New Mechanism Response Tamoxifen Therapy Breast Cancer Patients</brief_title>
	<detailed_description>Women abnormal mammogram suspicious mass undergo diagnostic core biopsy analyze ER/PR HER2Neu expression . For patient ER positive , P53 stain do . Women present tumor Allred score 3 great status approach participate . Women randomize either standard care surgical therapy 4 week intervention Tamoxifen 20mg daily 4 week prior surgery . During intervention , blood draw do measure level tamoxifen metabolite blood test polymorphism may decrease level active metabolite . Women undergo two blood draw PK/PD one pharmacogenomics .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>The patient must consent study must sign approve consent form conform institutional guideline The patient must 18 year old Core biopsy definitively demonstrate invasive carcinoma Invasive carcinoma ERά receptor positive The tumor approximately 1 cm , least 5mm account variability image image occult disease ( physical exam , mammography , ultrasound ) . Patients surgical excision tumor part standard care management ECOG 0 1 Negative serum urine βhCG pregnancy test screening patient childbearing potential ( routinely do premenopausal surgery ) Consent participate DBBR Male patient eligible study Female patient inoperable tumor patient undergo neoadjuvant chemotherapy Patients diagnosis FNA cytology Pregnant lactating woman Prior therapy breast cancer , include irradiation , chemo , immuno and/or hormonal therapy Patients receive hormonal therapy , e.g. , birthcontrol pill , ovarian hormonal replacement therapy , infertility medication , etc . eligible Nonmalignant systemic disease ( cardiovascular , renal , hepatic , etc . ) would preclude patient subjected surgical excision Psychiatric addictive disorder would preclude obtain informed consent Patients know suspected hypercoagulable syndrome history venous arterial thrombosis , stroke , TIA , pulmonary embolism Women postmenopausal define menses least 12 month Women selective serotonin reuptake inhibitor ( SSRI ) SSRI inhibit metabolism tamoxifen Women noninvasive disease microinvasion eligible Women undergo neoadjuvant chemotherapy eligible Women currently tamoxifen prevention eligible Patients shall receive herbal/alternative therapy flaxseed soy product black cohosh . Patients know mutation p53 ( Li Fraumeni Syndrome )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ER positive</keyword>
	<keyword>Tamoxifen</keyword>
</DOC>